About the Project
WGS, RNA-Seq and DNA methylation profiling of >350 tumour samples showed actionable events in only 70% of the patients. High-throughput drug testing on 85 patient-derived samples yielded unexpected efficacy patterns for single agent targeted drugs without an associated predictive biomarker, but clinical trials for paediatric cancer have proven that treatment with single agents is insufficient in most cases. The current study aims to integrate PRISM molecular profiling and in vitro drug efficacy datasets to identify novel biomarker-drug response associations and predict effective drug combinations for paediatric cancer by developing novel bioinformatic algorithms. Publicly available databases such as DepMap, CancerrXGene and NCI-ALMANAC that contain in vitro efficacy data for single drugs and drug combinations alongside molecular characterisation of the used model systems will be exploited for algorithm optimisation and deeper integrative analysis. Novel discovered biomarker-drug response associations and drug combinations will be validated in vitro and in vivo in patient-derived model systems to guide future clinical trials for paediatric cancer treatment.
To help us determine your suitability for postgraduate studies with us could you please send through a copy of your full academic transcript. All students at the Institute must fulfil the requirements for enrolment at UNSW to undertake their PhD with us as well as obtain a scholarship that will cover both your living expenses and tuition fees.
Why not add a message here
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.